Blog

  • Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Roger Godsiff on 2016-01-21.

    To ask the Secretary of State for Health, whether there is any requirement for NHS bodies which outsource health services to ensure that companies with which they contract are fully insured.

    George Freeman

    Clinical commissioning groups and NHS England, when commissioning foundation trusts, NHS trusts and others to deliver non-primary care clinical services, must do so using the NHS Standard Contract published each year by NHS England.

    The NHS Standard Contract requires the provider of clinical services to “put in place and maintain appropriate indemnity arrangements in respect of:

    – employers’ liability;

    – clinical negligence;

    – public liability; and

    – professional negligence.

  • Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Roger Godsiff on 2016-01-21.

    To ask the Secretary of State for Health, how much compensation the NHS has paid to patients who were injured by healthcare carried out by private contractors in each of the last five years.

    Ben Gummer

    The Department does not hold this information centrally; the answer has been supplied by the National Health Service Litigation Authority (NHS LA).

    The table below shows all payments made on claims against private providers as at 31 December 2015 (open and closed claims) for payment years 2010/11 to 2014/15.

    Year of Payment

    Damages £

    Defence Costs £

    Claimant Costs £

    Total Paid £

    2010/11
    2011/12
    2012/13
    2013/14
    2014/15

    3,213,372
    4,143,937
    8,132,597
    8,522,797
    8,905,057

    378,903
    621,887
    807,120
    868,765
    1,096,935

    1,251,698
    1,989,256
    3,312,219
    4,172,732
    4,504,967

    4,843,973
    6,755,080
    12,251,935
    13,564,293
    14,506,960

    Total

    32,917,760

    3,773,610

    15,230,871

    51,922,241

    Source: NHSLA

    Date: January 2016

    Prior to that date indemnity cover was provided by the referring National Health Service body. Since 1 April 2013 independent providers have been directly eligible for membership of the clinical negligence scheme for trusts. The figures in the table represent all private provider claims for each of the last five years.

  • Luciana Berger – 2016 Parliamentary Question to the Cabinet Office

    Luciana Berger – 2016 Parliamentary Question to the Cabinet Office

    The below Parliamentary question was asked by Luciana Berger on 2016-01-21.

    To ask the Minister for the Cabinet Office, with reference to the Prime Minister’s speech of 11 January 2016, on life chances, what the sources of the £60 million of social investment for drug and alcohol treatment are expected to be.

    Mr Rob Wilson

    The Government has actively supported the growth of the social investment market over the last five years. This includes through the establishment of Big Society Capital which is investing up to £600m in growing the social investment market, and the Social Investment Tax Relief which is incentivising individual investors to make social investments. Other social investors investing in social impact bonds include charitable trusts and foundations as well as institutional investors and dedicated social impact funds.

  • Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    Roger Godsiff – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Roger Godsiff on 2016-01-21.

    To ask the Secretary of State for Health, whether NHS bodies which carry out surgery to repair work performed by outsourcing companies are able to claim back the costs of carrying out that work.

    George Freeman

    Whether or not National Health Service bodies are able to claim back the costs depends on a number of circumstances. For instance:

    – A clinical commissioning group (CCG) may have placed a contract for elective surgery with an independent sector provider. A patient treated in this provider’s hospital may experience complications and require further treatment, which has to be arranged under the CCG’s separate contract with the local NHS trust or foundation trust (FT) (perhaps because it has the facilities to carry out more specialist treatment); or

    – An NHS trust or FT may sub-contract surgical procedures to an independent sector provider. Again, a patient treated at the sub-contractor’s hospital may experience complications and require further treatment, which has to be carried out by the NHS Trust or FT (again, because it has the facilities to carry out more specialist treatment).

    The terms of such subcontracts are not nationally prescribed, but it would be usual for such a sub-contract to require the sub-contractor to indemnify the NHS provider for the cost it incurs as a result of negligent or inadequate treatment on the part of the sub-contractor.

    However, it is important to be clear that complications after surgery are not necessarily associated with negligence. It is normal for patients experiencing complications to be referred to the hospital which can provide the best care. In these circumstances, each NHS provider will normally be paid by the relevant NHS commissioner for the specific service it has provided to the patient.

    In the first example, the NHS trust or FT will be paid in full by its local CCG for the further treatment it has provided, at the normal national prices laid down in the National Tariff Payment System. Normally, the CCG would also have paid for the initial treatment provided by the independent sector provider, but if there is evidence of breach of contract or negligence, the CCG would be entitled to be indemnified for the additional costs of further treatment.

    In the second example, the NHS provider is responsible to the commissioner both for the treatment it has carried out itself and under sub-contract by the independent sector provider. It will therefore be paid by its CCG at National Tariff prices for all the operations that have been undertaken at both hospitals – though, again, this would be subject to the potential for the CCG to withhold payment to in a clear case of negligence or breach of contractual requirements. Payment between the NHS provider and its sub-contractor would be a matter for those parties to agree locally between themselves, as a part of their sub-contract.

  • Chris Heaton-Harris – 2016 Parliamentary Question to the Department of Health

    Chris Heaton-Harris – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Chris Heaton-Harris on 2016-01-21.

    To ask the Secretary of State for Health, for what reasons the age at which the death of people with learning disabilities is classified as premature has been set at 60 in the draft NHS Outcomes Framework.

    Alistair Burt

    The Department worked with Public Health England (PHE) and the confidential inquiry into premature deaths of people with learning disabilities (CIPOLD) team at the Norah Fry Centre, University of Bristol to define the learning disability mortality indicator in the NHS Outcomes Framework. The placeholder indicator was set at age 60 based on the findings of the CIPOLD at the time which identified the mean age of death in people with learning disability as 60 years old.

    The Department, NHS England, PHE and the Norah Fry Centre are currently reviewing the definition of the indicator to establish if there is evidence to support it being redefined and to establish a robust and stable data source in order for the indicator to be reported and measured.

  • Jeremy Lefroy – 2016 Parliamentary Question to the Department of Health

    Jeremy Lefroy – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jeremy Lefroy on 2016-01-21.

    To ask the Secretary of State for Health, what estimate he has made of the (a) cost to the economy and (b) number of deaths attributable to antimicrobial resistance in the last 12 months for which figures are available; whether he has made such estimates for future years; and if he will make a statement.

    Jane Ellison

    A broad estimate of the cost of antimicrobial resistance to the National Health Service is £180 million per annum.

    Antimicrobial resistance is a global problem. In the longer term, a forecast of the global economic costs and deaths attributable to antimicrobial resistance is available from the independent review on antimicrobial resistance led by Lord O’Neill of Gatley. His review estimates that drug-resistant infections could kill an extra 10 million people globally every year by 2050, and have a cumulative cost to the world of around $100 trillion in lost output.

    The United Kingdom is taking the lead in addressing antimicrobial resistance globally, investing £265 million in the Fleming Fund to strengthen surveillance of drug resistance and laboratory capacity in developing countries.

  • David Crausby – 2016 Parliamentary Question to the Department of Health

    David Crausby – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Crausby on 2016-01-21.

    To ask the Secretary of State for Health, what steps his Department is taking to improve access to specialist care for people with muscular dystrophy.

    Jane Ellison

    Through the Mandate we have asked NHS England to make measurable progress towards making our health service among the best in Europe at supporting people with long-term conditions such as muscular dystrophy, to live healthily and independently, with much better control over the care they receive.

    NHS England commissions specialised neurological services at a national level, including for patients with muscular dystrophy. The neurosciences service specifications set out that patients with neuromuscular conditions, such as muscular dystrophy should have access to, including a multidisciplinary team (MDT) to will assess, diagnose and provide support. The MDT team will include neuromuscular consultants, neuromuscular physiotherapists, specialist nurses, occupational therapists, speech and language therapists and other care professionals. One of the key service outcomes of the specification is that all patients with long-term neurological conditions have an individualised care plan.

  • David Crausby – 2016 Parliamentary Question to the Department of Health

    David Crausby – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Crausby on 2016-01-21.

    To ask the Secretary of State for Health, what steps are being taken to improve access to food hygiene score information in England.

    Jane Ellison

    The Food Standards Agency (FSA) has responsibility for the Food Hygiene Ratings Scheme. The FSA is currently collecting evidence on the impact of the mandatory display of food hygiene ratings at food outlets in Wales. The Government will consider this evidence carefully once it is available. In the meantime, the FSA will continue working with its local authority partners to encourage businesses to voluntarily display their ratings and to promote the scheme to consumers.

    Ratings are published on the FSA website (and via phone apps), and there is open access to the data.

  • Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Barry Sheerman on 2016-01-21.

    To ask the Secretary of State for Health, what steps his Department is taking to help prevent bleach and other ineffective treatments advertised as miracle cures being used to treat autism.

    Alistair Burt

    The Department is aware of the development of sodium chlorite being marketed as Miracle Mineral Solution (MMS) as a cure for autism. MMS is not a cure for autism.

    The Food Standards Agency has issued advice previously, first in 2010, that MMS is not safe and should not be sold as a supplement. Since then it has been working with local authorities across the country to share knowledge, and to investigate and prevent the sale of MMS and similar products.

  • Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Barry Sheerman on 2016-01-21.

    To ask the Secretary of State for Health, what steps his Department is taking to ensure that all GPs are trained in awareness of the diagnostic pathway for people seeking a diagnosis of autism.

    Alistair Burt

    In 2015, new statutory guidance building on the 2010 Autism Strategy, and the 2014 Think Autism update, set out expectations for local authorities and the National Health Service in relation to autism training. It is the responsibility for the General Pharmaceutical Council and the Nursing and Midwifery Council, to ensure newly qualified pharmacists and health visitors are equipped with the knowledge, skills and attitudes to provide high quality patient care. The Department has worked the Royal College of Nursing, and Skills for Health and Skills for Care, to develop autism training material. Health Education England is also working with the Royal Colleges and other stakeholders to increase awareness and knowledge of autism for NHS health professionals.

    The Department has also provided financial support to the Royal College of General Practitioners’ clinical priorities programme on autism which is undertaking practical work on autism awareness and training for general practitioners (GPs). GPs should be aware of what the local arrangements are for making referrals for autism diagnosis and how to access appropriate post-diagnostic interventions.

    NHS England has commenced a programme to visit clinical commissioning groups (CCGs) to identify and share good practice in accessing timely autism diagnosis and post diagnostic support. NHS England with support from the Association of Directors of Adult Social Services is to visit a selection of areas to talk to CCGs and local authorities about their Autism Diagnostic Care Pathways. A report on the work will be completed by the end of April 2016.

    We know that people with autism can experience common mental health conditions such as depression and anxiety, as well as other mental illnesses. Over £400 million has been invested in Improving Access to Psychological Therapies to ensure access to talking therapies for those who need them, including those with autism.